Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Epigenomics AG - Asset Resilience Ratio
Epigenomics AG (EPGNF) has an Asset Resilience Ratio of 14.14% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2020)
This chart shows how Epigenomics AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Epigenomics AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $961.00K | 14.14% |
| Total Liquid Assets | $961.00K | 14.14% |
Asset Resilience Insights
- Moderate Liquidity: Epigenomics AG has 14.14% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Epigenomics AG Industry Peers by Asset Resilience Ratio
Compare Epigenomics AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Epigenomics AG (2007–2020)
The table below shows the annual Asset Resilience Ratio data for Epigenomics AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 14.14% | $961.00K | $6.80 Million | +7.85pp |
| 2019-12-31 | 6.29% | $880.00K | $13.99 Million | +3.30pp |
| 2018-12-31 | 2.99% | $653.00K | $21.83 Million | -1.59pp |
| 2017-12-31 | 4.58% | $905.00K | $19.77 Million | +0.44pp |
| 2016-12-31 | 4.13% | $753.00K | $18.22 Million | -2.09pp |
| 2015-12-31 | 6.22% | $784.00K | $12.60 Million | -0.67pp |
| 2014-12-31 | 6.89% | $780.00K | $11.32 Million | +0.12pp |
| 2013-12-31 | 6.77% | $750.00K | $11.08 Million | -0.63pp |
| 2012-12-31 | 7.40% | $509.00K | $6.88 Million | +0.06pp |
| 2011-12-31 | 7.34% | $1.43 Million | $19.46 Million | +1.97pp |
| 2010-12-31 | 5.36% | $1.81 Million | $33.84 Million | -7.98pp |
| 2009-12-31 | 13.34% | $2.18 Million | $16.35 Million | +2.07pp |
| 2008-12-31 | 11.27% | $2.29 Million | $20.28 Million | -3.44pp |
| 2007-12-31 | 14.71% | $3.37 Million | $22.91 Million | -- |